Arkolith/Insider Trading/IGC/Form 4

Prins Richard K

DirectorIGC Pharma, Inc. (IGC) · full profile →Form 4 · filed Apr 6, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
4
2 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 1, 2026Option exercise(M)100K—$01.5M
Apr 1, 2026Option exercise(M)70K—$01.5M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Apr 1, 2026Option exercise(M)100K—$00
Apr 1, 2026Option exercise(M)70K—$070K

Transaction Codes

M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001185185-26-001286) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML